司库奇尤单抗治疗银屑病、银屑病关节炎和强直性脊柱炎患者中炎症性肠病发病率:21项临床试验汇总回顾分析
结果显示IBD事件不常见,且各适应症的每年暴露调整发病率未随司库奇尤单抗治疗时间延长而增加。
要点
- 司库奇尤单抗治疗患者中IBD事件(含CD、UC、IBDU)不常见。
- 各适应症的暴露调整发病率未随治疗时间延长而增加。
- 银屑病关节炎和强直性脊柱炎患者中报告了部分新发IBD病例。
核心结论
- 在21项临床试验7355例患者的汇总分析中,司库奇尤单抗治疗期间IBD事件(包括CD、UC和IBDU)不常见。
研究设计与样本
- 安全性分析按适应症评估累积IBD发病率和每年发病率,采用暴露调整发病率(每100患者年)。
主要发现
- 银屑病患者5181例中,UC 14例、CD 5例、IBDU 1例,暴露调整发病率分别为0.13、0.05和0.01,其中14例为新发。
- 银屑病关节炎患者1380例中,UC 3例、CD 3例、IBDU 2例,暴露调整发病率分别为0.08、0.08和0.05,其中7例为新发。
- 强直性脊柱炎患者794例中,UC 4例、CD 8例、IBDU 1例,暴露调整发病率分别为0.2、0.4和0.1,其中9例为新发。
- 每年分析中,各适应症的暴露调整发病率未随司库奇尤单抗治疗时间延长而增加。
临床怎么用
- 临床使用司库奇尤单抗治疗银屑病、银屑病关节炎或强直性脊柱炎时,IBD事件不常见,但需关注新发IBD病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Here, we present the reported incidence rates of inflammatory bowel disease (IBD) in patients receiving treatment with secukinumab for psoriasis (PsO), psoriatic arthritis (PsA) or ankylosing spondylitis (AS), in a pooled analysis of 21 clinical trials. METHODS: Data from all patients who had received at least one dose of secukinumab were included. Safety analyses were conducted to evaluate cumulative IBD rates as well as per-year rates, by indication. Crohn's disease (CD), ulcerative colitis (UC) and IBD unclassified (IBDU) events were analysed using exposure-adjusted incidence rates (patient incidence rates per 100 patient-years (PY)). RESULTS: A total of 7355 patients with a cumulative exposure of 16 226.9 PY were included in the pooled analysis. Among 5181 patients with PsO, there were 14 cases of UC, 5 cases of CD and 1 case of IBDU, with exposure adjusted incidence rates (EAIRs) of 0.13, 0.05 and 0.01, respectively. Of these 20 cases, 14 were new-onset. In 1380 patients with PsA, there were 3 cases of UC, 3 cases of CD and 2 cases of IBDU (EAIRs 0.08, 0.08 and 0.05); 7 of these represented new-onset cases. Among 794 patients with AS, there were 4 cases of UC, 8 cases of CD and 1 case of IBDU (EAIRs 0.2, 0.4 and 0.1); 9 were new-onset cases. In the per year analysis, the EAIRs for each indication did not increase over time with secukinumab treatment. CONCLUSIONS: In this pooled secukinumab safety analysis of 7355 patients across 21 clinical trials, cases of IBD events (including CD, UC and IBDU) were uncommon.
引用
- Schreiber S, Colombel JF, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019. PMID: 30674475. doi:10.1136/annrheumdis-2018-214273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。